Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
- 1 May 2016
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (5) , 3227-3231
Abstract
We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.Keywords
Funding Information
- HHS | National Institutes of Health (K08AI114883)
- NIH (R21AI222037)
This publication has 24 references indexed in Scilit:
- Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US HospitalsClinical Therapeutics, 2015
- Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013Antimicrobial Agents and Chemotherapy, 2015
- Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. HospitalsAntimicrobial Agents and Chemotherapy, 2014
- Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for ResistanceAntimicrobial Agents and Chemotherapy, 2014
- In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative OrganismsAntimicrobial Agents and Chemotherapy, 2012
- In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug ResistanceAntimicrobial Agents and Chemotherapy, 2010
- Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolatesInternational Journal of Antimicrobial Agents, 2009
- Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2009
- Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millenniumClinical Microbiology and Infection, 2007
- Interplay of Efflux System, ampC , and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2006